Pfizer Inc. PFE
28.67
0.26
0.92%
as of 25 Sep
- Market cap
- $161.7B
- P/E
- 37.7×
Follow PFE
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years,
Insider Buys
alert about insiders buying in the last 12 month
Pfizer Inc. (PFE) P/S ratio
As of 25 September 2026, Pfizer Inc. (PFE) trades at a P/S ratio of 2.6×. Over the past ten years it has ranged from 2.0× (April 2025) to 7.4× (December 2020); the current reading is higher than 24% of that period. That is below the Drug Manufacturers General industry median of 3.3× and below the Healthcare sector median of 3.8×.
P/S ratio, daily
Annual
| Period | P/S ratio | Change |
|---|---|---|
| FY2025 | 2.3× | (4.26%) |
| FY2024 | 2.4× | (16.17%) |
| FY2023 | 2.8× | (0.85%) |
| FY2022 | 2.8× | (30.17%) |
| FY2021 | 4.1× | (17.12%) |
| FY2020 | 4.9× | (2.99%) |
| FY2019 | 5.1× | (15.04%) |
| FY2018 | 6.0× | 51.64% |
| FY2017 | 3.9× | 8.83% |
| FY2016 | 3.6× | (6.80%) |
Quarterly
| Period | P/S ratio | Change |
|---|---|---|
| Jun 2026 | 2.2× | (14.64%) |
| Mar 2026 | 2.5× | 11.62% |
| Dec 2025 | 2.3× | (1.99%) |
| Sep 2025 | 2.3× | 6.87% |
| 42 more quarters | Free account |
Against its own ten years
Low 2.0×
High 7.4×
Ten-year median
3.7×
Current reading's percentile
24
P/S ratio against peers
| Company | P/S ratio |
|---|---|
| SNY Sanofi compare | 1.7× |
| GSK GSK PLC Sponsored ADR compare | 2.2× |
| PFE Pfizer Inc. | 2.6× |
| BMY Bristol Myers Squibb Company compare | 2.6× |
| NVO Novo Nordisk A/S compare | 3.3× |
| AZN AstraZeneca PLC compare | 4.2× |
| NVS Novartis AG compare | 4.9× |
| AMGN Amgen Inc. compare | 5.9× |
| GILD Gilead Sciences, Inc. compare | 6.2× |
| Drug Manufacturers General industry median | 3.3× |
| Healthcare sector median | 3.8× |
| Market median | 2.0× |
What P/S ratio is
Price to Sales Ratio shows how much investors pay for each dollar of a company’s annual sales, whether or not it is profitable.
(Stock Price × Shares (Basic, Weighted) (latest quarter)) ÷ Revenue (TTM)
More on PFE
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement